Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant mycobacterium tuberculosis allergen ESAT6-CFP10 + tuberculin purified protein derivative
- Development stage
- Unknown
- Lead developer
- Anhui Zhifei Longcom Biopharmaceutical
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intradermal
01
Overview
ESAT6-CFP10 + TB-PPD refers to a diagnostic combination used in clinical trials to compare the performance of a novel recombinant tuberculosis skin test against the standard tuberculin purified protein derivative (PPD). ESAT6-CFP10, also known as C-TST or the EC skin test, is a recombinant fusion protein comprising two Mycobacterium tuberculosis-specific antigens: Early Secretory Antigenic Target 6 (ESAT-6) and Culture Filtrate Protein 10 (CFP-10). These antigens are absent in the BCG vaccine and most non-tuberculous mycobacteria, allowing the test to differentiate between TB infection and prior BCG vaccination. Developed by Anhui Zhifei Longcom Biologic Pharmacy, the combination is administered via intradermal injection to evaluate sensitivity and specificity in diagnosing latent and active tuberculosis. The diagnostic readout is based on the diameter of induration at the injection site, reflecting a delayed-type hypersensitivity (DTH) response.
- Brand names
- C-TST
- Other names
- ESAT6-CFP10ESAT-6-CFP10ESAT 6-CFP10TB-PPDrecombinant ESAT-6-CFP-10recombinant Mycobacterium tuberculosis allergen ESAT6-CFP10tuberculin purified protein derivative
02
Targets
MHC I (MHC class I})T-cell receptor specific for ESAT-6/CFP-10 peptide–MHC class I complexesMHC II (Major histocompatibility complex class II receptor)T-cell receptor specific for Purified Protein Derivative-derived peptide–Major Histocompatibility Complex class II complexT-cell receptor specific for ESAT-6/CFP-10 peptide–MHC class II complexes
Beyond the preview
Go deeper on recombinant mycobacterium tuberculosis allergen ESAT6-CFP10 + tuberculin purified protein derivative.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant mycobacterium tuberculosis allergen ESAT6-CFP10 + tuberculin purified protein derivative.